OSR’s Vaximm Reports VXM01 Shines Against Glioblastoma in Phase 2a Trail

March 26, 2025

DENVER, Colo., Mar 26, 2025 (247marketnews.com)- Vaximm, an OSR Holdings (NASDAQ:OSRH) subsidiary, shared results from its open-label Phase 2a trial pairing VXM01, an oral anti-VEGFR-2 vaccine, with avelumab (a PD-L1 inhibitor) showing a promising safety profile in recurrent glioblastoma (GBM) patients. Partnered with Merck KGaA, Darmstadt, Germany, this trial’s success signals VXM01’s potential as a game-changer, greenlighting deeper dives into this brutal brain cancer.

The combo proved well-tolerated; most side effects were mild to moderate, mirroring avelumab’s solo safety data with no new red flags. Of 11 serious adverse events (SAEs), 81.8% tied to GBM itself, not VXM01, spotlighting the therapy’s gentle touch in a fragile population. In non-resected patients, a 12% objective response rate (ORR) emerged—12% saw partial remission, 4% held stable—hinting at clinical upside worth chasing. Resected patients’ overall survival (OS) spanned 2.2 to 46.5 months, a wild range begging for subgroup studies. Across all 25 participants, median progression-free survival (PFS) hit 2.7 months (range 0.3-22.1) and median OS reached 11.1 months (range 3.8-38.2)—encouraging against GBM’s grim norms of 1.5-6 months PFS and 2-9 months OS (Birzu et al., 2020).

Dr. Constance Hoefer, Vaximm’s CEO, reported, “The completion of this Phase 2a study is a significant milestone for Vaximm AG, as it provides strong evidence that VXM01, in combination with avelumab is generally well-tolerated in patients with recurrent glioblastoma. We are encouraged by these early results and the potential to improve outcomes for patients with this aggressive cancer. We remain committed to advancing VXM01 as a key therapeutic candidate for the treatment of glioblastoma, other cancers and other diseases where VXM01 may have positive impact on treatment outcomes.”

Tumor shrinkage popped up across sizes. Biomarkers hinted at predictors of VXM01’s kick, fueling optimism. With a $5 billion GBM market in sight, VXM01’s next steps could redefine treatment.

VXM01, a live bacterial vaccine tweaked to carry VEGFR-2, wakes killer T-cells to shred tumor blood vessels and, in GBM, cancer cells directly.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (OSRH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.